Grünenthal has consistently invested in research and development in recent years. 26 % of our turnover from 2012 went back into our research and development. Grünenthal’s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We focus on the intensive search for new ways to treat pain better, more sustainably and with fewer side-effects than before.
Our employees in interdisciplinary teams work in optimum spatial proximity in order to put this strategy into practice. We have a unique opioid research program, extensive experience in the development of new dosage forms and innovative technology platforms as well as comprehensive expertise in the field of technical and preclinical substance development.